Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

yellow fever vaccine (Rx)Brand and Other Names:YF Vax

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injection [17D-204 strain]

  • ≥4.74 log10 plaque-forming units/0.5mL
more...

Yellow Fever

Prophylaxis: 0.5 mL SC ≥10 days before travel

A single, lifetime dose of yellow fever vaccine is sufficient for most people traveling to endemic areas, although some high-risk groups may benefit from a booster dose according to CDC's Advisory Committee on Immunization Practices

MMWR June 19, 2015:64(23);647-650

Booster/additional dose for high-risk groups

  • A single primary dose of yellow fever vaccine provides long-lasting protection and is adequate for most travelers
  • Additional doses of yellow fever vaccine recommended for
    • Women who were pregnant (regardless of trimester) when they received their initial dose of yellow fever vaccine should receive 1 additional dose before their next travel that puts them at risk for yellow fever virus infection
    • Persons who received a hematopoietic stem cell transplant after receiving a dose of yellow fever vaccine and who are sufficiently immunocompetent to be safely vaccinated should be revaccinated before their next travel that puts them at risk for yellow fever virus infection
  • Booster dose for high risk after 10 yr
    • A booster dose may be given to travelers who received their last dose of yellow fever vaccine at least 10 yr previously and who will be in a higher-risk setting based on season, location, activities, and duration of their travel
    • Persons who were infected with HIV when they received their last dose of yellow fever vaccine should receive a dose every 10 yr
    • Travelers who plan to spend a prolonged period in endemic areas or those traveling to highly endemic areas such as rural West Africa during peak transmission season or an area with an ongoing outbreak
    • Laboratory workers who routinely handle wild-type yellow fever virus should have yellow fever virus–specific neutralizing antibody titers measured at least every 10 yr to determine if they should receive additional doses of the vaccine
    • For laboratory workers who are unable to have neutralizing antibody titers measured, yellow fever vaccine should be given every 10 yr as long as they remain at risk

Dosage Forms & Strengths

injection [17D-204 strain]

  • ≥4.74 log10 plaque-forming units/0.5mL
more...

Yellow Fever

>6 months (off-label): 0.5 mL SC x 1 dose ≥10 days before travel

>9 months: 0.5 mL SC x 1 dose ≥10 days before travel

A single, lifetime dose of yellow fever vaccine is sufficient for most people traveling to endemic areas, although some high-risk groups may benefit from a booster dose according to CDC's Advisory Committee on Immunization Practices

MMWR June 19, 2015:64(23);647-650

Booster/additional dose for high-risk groups

  • A single primary dose of yellow fever vaccine provides long-lasting protection and is adequate for most travelers
  • Additional doses of yellow fever vaccine recommended for
    • Persons who received a hematopoietic stem cell transplant after receiving a dose of yellow fever vaccine and who are sufficiently immunocompetent to be safely vaccinated should be revaccinated before their next travel that puts them at risk for yellow fever virus infection
  • Booster dose for high risk after 10 yr
    • A booster dose may be given to travelers who received their last dose of yellow fever vaccine at least 10 yr previously and who will be in a higher-risk setting based on season, location, activities, and duration of their travel
    • Persons who were infected with HIV when they received their last dose of yellow fever vaccine should receive a dose every 10 yr
    • Travelers who plan to spend a prolonged period in endemic areas or those traveling to highly endemic areas such as rural West Africa during peak transmission season or an area with an ongoing outbreak
Next

Interactions

Interaction Checker

yellow fever vaccine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967

            1-10%

            Headache (5-10%)

            Chills (5-10%)

            Low-grade fever (5-10%)

            Myalgia (5-10%)

            Frequency Not Defined

            Meningoencephalitis

            Seizures

            Rash

            Urticaria

            Pain

            Warmth

            Erythema

            Guillain-Barre syndrome

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity to chicken eggs

            Acute or febrile disease

            Immunosuppressed patients (due to malignancy, radiation, or medications)

            Infants <6 months (per CDC if exposure to the yellow fever virus is unavoidable)

            Infants <9 months (per manufacturer due to risk of encephalitis)

            Lactation

            Cautions

            Vial stopper contains natural latex rubber; epinephrine should be available when vaccine

            Syncope accompanied by visual disturbances, tonic-clonic movements, or weakness reported with injectable vaccines

            Hypersensitivity to egg or chicken protein may be tested with a 1:10 vaccine dilution utilizing a scratch, prick, or puncture test; if vaccine is essential, desensitize individual before administering full dose

            Oral prednisone or other systemic corticosteroid therapy may have an immunosuppressive effect on recipients of yellow fever vaccine that potentially decreases immunogenicity and increases the risk of adverse events

            Postpone immunization in acute or febrile illness; low grade fever not a reason to postpone vaccination

            Risk of encephalitis may be increased (theoretically) in patients who are immunosuppressed

            Following vaccination, wait two weeks before donating blood

            Effective immunity may not occur in all vaccinated patients

            Malnourished persons may have decreased response to vaccination

            Previous
            Next

            Pregnancy

            Pregnancy Category: C

            Lactation: There is a theoretical risk of transmission of vaccine components to the infants from breast-feeding mothers, lactation constitutes a contraindication, particularly when infants are <9 months of age because of the risk of encephalitis

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Live, attenuated virus stimulates active immunity to Yellow fever; conveys active immunity via stimulation of production of endogenously produced antibodies

            Pharmacokinetics

            Onset: 7-10 days

            Duration of immunity: 30 yr to life

            Previous
            Next

            Administration

            SC Preparation

            Reconstitute 1 dose vial with 0.6 mL supplied diluent and 5 dose vial with 3 mL supplied diluent

            Store refrigerated at 2-8°C (35-46°F); do not freeze

            Storage

            Store refrigerated at 2-8°C (35-46°F)

            Do not freeze

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.